Partnership's Custom Built Solution Advances Toward Commercialization and Roll-Out for Department of Defense DENVER, Colo., Oct. 2 /PRNewswire-FirstCall/ -- CAMRIS International, a professional services firm that provides expert technical resources and innovative technologies ("CAMRIS"), and Global Med Technologies(R), Inc. ("Global Med") (OTC:GLOB) (BULLETIN BOARD: GLOB) , an international e-Health, medical information technology company, today announced the award and advancement to the next phase for a project to develop and commercialize a global profile database to track blood donor identity, health and travel history for the U.S. Military worldwide. Terms of the agreement were not disclosed. (Logo: http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO) Major Ileana Hauge, Chief of Applied Toxicology Research at Wright-Patterson Air Force Base, stated, "The U.S. Air Force has realized for some time that a commercial off-the-shelf solution to manage the Armed Services Blood Program is impractical. CAMRIS and Wyndgate have demonstrated that a custom solution built to our specific needs from the backbone of the El Dorado Donor(TM), Donor Doc(TM) and SafeTrace(R) platforms is the winning alternative. These vendors have demonstrated their merit and we have confidence in the outcome as we progress through Phase-II." CAMRIS has partnered with Global Med's Wyndgate Technologies(R) division since 2006. Last year, under a Department of Defense Small Business Innovation Research (SBIR) Program, the partnership won a Phase-I competitive bid, demonstrating the scientific and technical merit and feasibility of developing a global software system to provide universal access to donor identity, deferrals and travel history. The goal is to create continuity across blood bank facilities, thereby helping to increase the safety of the Armed Forces' global blood supply. Phase-I included demonstration of a prototype solution modeled after the platform of Wyndgate's El Dorado Donor, Donor Doc, and SafeTrace solutions. After winning the Phase-I award, the companies submitted and recently won a joint proposal to continue the project in Phase-II, to customize the software for clinical settings to support robust, accurate and consistent performance and provide a secure interface to be used worldwide. The Phase-II award is significant in that it advances the project from prototype through development, culminating in potential commercialization and roll-out. Merits of the Phase-II advancement include confidence from the Air Force and Armed Services Blood Program that the project has technical and scientific merit, that commercial application is promising, and that there is evidence of the competency and qualifications of the principal investigator team to deliver results. Ultimately, the software solution may be employed to fulfill the needs not only of the U.S. Air Force, U.S. Navy and U.S. Army, but also of NATO alliance countries as the need to track and move blood increases with globalization of services. After an extensive evaluation by the Wright Patterson Air Force Research Laboratory, an independent report determined that CAMRIS and Wyndgate exhibited dedicated technical and professional resources committed to the SBIR project, and that their software products were proven in the industry and trusted by blood bankers. The partners also possess a broad continuum of knowledge about SBIR. In addition, the evaluation concluded that CAMRIS and Wyndgate have proven project management and blood computer database system implementation and support experience and have the documented ability to deliver solutions that solve complex and diverse business needs that will be needed globally in the Armed Forces and with NATO. Carlos Rivera, CEO of CAMRIS International, stated, "We believe the CAMRIS/Wyndgate team has a unique combination of experience in health care, technological innovation, and support for the Armed Forces. Mr. Rivera continued, "We are confident that this will be the perfect opportunity to combine our capabilities and continue into a future Phase-III in which the solution has the potential to be commercialized among all government agencies domestically and internationally." Mick Ruxin, M.D., Chairman and CEO of Global Med Technologies, Inc., stated, "We are proud to advance to Phase-II with this SBIR." Dr. Ruxin continued, "The confidence placed in us by the Department of Defense is a testament to our commitment to help the U.S. Armed Forces and NATO to provide safety and security for the global military blood supply. We are excited to add yet another dimension to our global footprint as we move forward with CAMRIS and the dedicated individuals at Wright Patterson Air Force Base." About CAMRIS International CAMRIS delivers comprehensive and customized services in the areas of knowledge management, public health, international development, medical services and technology solutions. CAMRIS is a unique, fast growing, dynamic small business and has project experience spanning more than 1,300 completed tasks and activities for more than 300 clients over the past 50 years. CAMRIS International is a certified 8(a), Service Disabled Veteran Owned, and a certified Maryland MBE, facility-cleared, small disadvantaged business. For more information about CAMRIS International, please call (301) 770-6000 or visit http://www.camrisinternational.com/ or http://www.camris.net/ About Global Med Technologies, Inc. Global Med Technologies(R), Inc. is an international medical software company which develops regulated and non-regulated software products and services for the healthcare industry. As a leading provider of blood and laboratory software applications and services, Global Med's products are deployed in 20 countries and serve over 1,600 transfusion centers, blood banks and laboratories. Global Med's U.S. division, Wyndgate Technologies(R), provides Vein-to-Vein(R) tracking through its Donor Doc(TM), SafeTrace(R), SafeTrace Tx(R) and El Dorado Donor(TM) software products. Each year, Wyndgate's products and services manage more than eight million blood components, representing over 27% of the U.S. blood supply. Global Med's European subsidiary, Inlog, SA, is a leading provider of donor center and transfusion management systems as well as cellular therapy software, laboratory information systems and quality assurance medical software systems internationally. Inlog's products include EdgeBlood*, EdgeTrack*, EdgeCell, EdgeLab and SAPA. Global Med's U.S. division, eDonor(R), provides a web-based donor relationship management system that integrates recruitment, scheduling, retention and fulfillment for national as well as local community blood centers and hospitals. eDonor's products and services are designed to complement Global Med's strong line of international blood management and laboratory information software and service solutions. Global Med's U.S. subsidiary, PeopleMed(R), Inc., provides cost-effective customized software validation, consulting and compliance solutions to hospitals and donor centers. For more information about Global Med's products and services, please call 800-996-3428 or visit http://www.globalmedtech.com/, http://www.peoplemed.com/, http://www.inlog.com/, http://www.edonor.com/, and http://www.wyndgate.com/. *FDA 510(k) clearance required prior to sales in the U.S. This news release may include statements that constitute forward-looking statements, usually containing the words "believe," "estimate," "project," "expects" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this news release. http://www.newscom.com/cgi-bin/prnh/20040226/GLOBALMEDLOGO http://photoarchive.ap.org/ DATASOURCE: Global Med Technologies, Inc. CONTACT: Carlos Rivera, CEO, +1-301-770-6000, ext. 106, , or Dr. Maria Trujillo, Principal Investigator, +1-301-770-6000, ext. 131, , both of CAMRIS International; or Michael I. Ruxin, M.D. of Global Med Technologies, Inc., +1-303-238-2000, ; or Investors, Paul Holm, President of portfolio pr. +1-212-888-4570, , for Global Med Technologies, Inc. Web site: http://www.globalmedtech.com/ http://www.wyndgate.com/ http://www.camrisinternational.com/ http://www.camris.net/

Copyright